Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriate investigated and resolved. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
BackgroundMyroides spp. are common environmental organisms and they can be isolated predominantly in water, soil, food and in sewage treatment plants. In the last two decades, an increasing number of infections such as urinary tract infections and skin and soft tissue infections, caused by these microorganisms has been reported. Selection of appropriate antibiotic therapy to treat the infections caused by Myroides spp. is difficult due to the production of a biofilm and the organism’s intrinsic resistance to many antibiotic classes.Case presentationWe report the case of a 69-year-old immunocompromised patient who presented with repeated episodes of macroscopic haematuria, from Northern Italy.A midstream urine sample cultured a Gram negative rod in significant amounts (> 105 colony-forming units (cfu)/mL), which was identified as Myroides odoratimimus. The patient was successfully treated with trimethoprim/sulfamethoxazole after antibiotic susceptibility testing confirmed its activity.ConclusionThis case underlines the emergence of multidrug resistant Myroides spp. which are ubiquitous in the environment and it demands that clinicians should be more mindful about the role played by atypical pathogens, which may harbour or express multidrug resistant characteristics, in immunocompromised patients or where there is a failure of empiric antimicrobial therapy.
N ephrologists often see patients who have a family history of chronic kidney disease (CKD), but the clinical utility of this information is not always clear. Alongside comorbid conditions (such as diabetes, hyper
Background and Aims Belluno is a mountainous province of 3610 Km2, with a low population density (56 people/Km2), and an high ISTAT old age index of 228. Four HemoDialysis (HD) Centers assist 112 patients, who spend up to 8 hours/week by ambulance to arrive at the HD Center, with a CO2 estimated emission (EE) up to 6.6 ton/year patient. The cost of in-Center HD may reach up to 61.000 €/year patient. Giving these premisis, we consider as first choice either Peritoneal Dialysis or Home HD (HDD), otherwise than in-Center HD. HHD can be Not assited HHD (NHHD), performed by the patient himself, or Assisted HHD (AHHD), the new HHD service which involves a nurse assistance at home. Both HHDs enables patients to stay at home, may improve patient’s quality of life, reduce the HD costs (32.000-34000 €/year patient), and may reduce the environmental burden of the healthcare procedures (CO2 EE of 0-2.3 ton/year patient). Method One patient have undertaken NHHD and other two the AHHD. Patient 1, on NHHD, is a 50 year old (y.o.) male, on HD since 9/2013. His Past Medical History (PMH) encompasses End Stage Renal Disease (ESRD) due to IgA Nephropathy, a previous kidney transplant, and hypertensive cardiopathy. Patient 2, on AHHD, is a 88y.o. woman, on HD since 01/2020. Her PMH includes ESRD due to multiple myeloma, and hypertension. Patient 3, on AHHD, is a 95y.o. male on HD since 09/2009. His PMH includes ESRD due to hypertensive nephropathy, atrioventricular block with pacemaker, hepatopathy. HHD is performed utilising: the NxStage System (Fresenius®) for NHHD, and the Dialog iQ® System (B.BRAUN®) for AHHD. The HD prescription plans 2 hours treatment for 6 times/week for NHHD, and 4 hours treatment for 3 times/week for AHHD. The total amount of the economical resoureces employed for HD comprise: HD equipment, healthcare-worker, and ambulance transportation (Figure). The EE of CO2 have been determined using a calculator (www.myclimate.org). The EE of CO2 for in-Centre HD comprise both those caused by patients and nurses (Figure). We assumed the same fuel consumption of a diesel Van for the ambulances one. We assumed that nurses use a diesel compact car to commute. Results All patients reported a significantly improved quality of life because they were able to avoid many hours of travel to reach the HD Center. Moreover, the patient on NHHD, appreciated an increased subjective wellness, a greater independence in setting the daily work and personal appointments, and a wider freedom in the eating and drinking habits. The economical resources that may be riallocated by the Healthcare System are up to 30.000 €/year patient. Finally, the environmental burden of the HD procedures may be significantly reduced, with a CO2 EE saved up to 6.6 ton/year patient (equal to 3 round-trip flights Venice-NY). Conclusion Home HD enable patients and their families to substantially improve their quality of life, provide a safe and effective dialysis treatment for the patients, contribute to operational efficiency of the healthcare system, and reduce both the economical impact and the environmental burden of hemodialysis. In conclusion, we believe both HHDs are exellent solution, in particular NHHD for active young patients, and AHHD for fragile patients without a caregiver, resulting in a better management and outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.